**S3 Text. Sensitivity analysis assuming patients with Genotype-3 HCV receive 24-week treatment of sofosbuvir and patients with non-Genotype-3 HCV receive 12-week treatment of sofosbuvir**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Country | 2014 Population1 | Adult population with HCV viraemia2 | HCV genotype distribution | | Price (USD PPP) | Price weighted by different duration of treatment according to genotype distribution (USD PPP) | Percentage of TPE | | | | Number of years worked | |
| Type 32 | Other2 | 10%3 | 50%\* | 75%\* | 100%\* | Average wage | Minimum wage |
| **Sofosbuvir** |  |  |  |  |  |  |  |  |  |  |  |  |
| Austria | 8,502,960 | 27,000 | 19.0% | 81% | $37,819.85 | $45,005.62 | 2.5% | 12.7% | 19.1% | 25.5% | 0.98 | 1.86 |
| Belgium | 11,283,680 | 69,000 | 19.0% | 81% | $37,662.53 | $44,818.42 | 3.7% | 18.6% | 27.9% | 37.2% | 0.93 | 1.48 |
| Canada | 35,711,400 | 245,000 | 22.3% | 78% | $33,578.76 | $41,066.82 | 3.7% | 18.3% | 27.4% | 36.5% | 0.85 | 1.78 |
| Denmark | 5,596,683 | 21,000 | 43.0% | 57% | $30,799.32 | $44,043.03 | 5.6% | 28.0% | 42.0% | 56.0% | 0.89 | 1.11 |
| Finland | 5,465,000 | 22,298 | 46.0% | 54% | $33,397.53 | $48,760.40 | 4.2% | 21.1% | 31.6% | 42.1% | 1.20 | 1.19 |
| France | 64,359,600 | 197,000 | 19.7% | 80% | $38,076.91 | $45,578.06 | 2.1% | 10.7% | 16.1% | 21.4% | 1.12 | 1.55 |
| [Germany](http://stats.oecd.org/OECDStat_Metadata/ShowMetadata.ashx?Dataset=POP_FIVE_HIST&Coords=%5bLOCATION%5d.%5bDEU%5d&ShowOnWeb=true&Lang=en) | 80,921,000 | 267,000 | 27.4% | 73% | $42,623.20 | $54,301.96 | 2.7% | 13.4% | 20.1% | 26.8% | 1.24 | 1.83 |
| Greece | 11,380,900 | 128,033 | 34.0% | 66% | $51,459.40 | $68,955.60 | 12.9% | 64.7% | 97.1% | 129.4% | 2.61 | 4.37 |
| Ireland | 4,609,900 | 30,000 | 39.0% | 61% | $43,383.16 | $60,302.59 | 5.9% | 29.5% | 44.2% | 58.9% | 1.13 | 2.06 |
| Italy | 61,417,630 | 768,000 | 3.6% | 96% | $45,704.77 | $47,350.14 | 11.5% | 57.6% | 86.4% | 115.1% | 1.36 | 1.09 |
| Japan | 126,948,800 | 1,252,000 | 0.0% | 100% | $37,970.60 | $37,970.60 | 5.2% | 26.1% | 39.1% | 52.1% | 1.06 | 2.02 |
| Netherlands | 16,918,490 | 22,298 | 29.3% | 71% | $35,778.23 | $46,261.25 | 1.4% | 6.8% | 10.2% | 13.5% | 0.91 | 1.52 |
| New Zealand | 4,388,200 | 48,192 | 35.0% | 65% | $41,937.77 | $56,615.99 | 20.9% | 104.7% | 157.0% | 209.3% | - | 2.00 |
| Norway | 5,137,000 | 23,000 | 28.1% | 72% | $28,092.07 | $35,985.94 | 3.9% | 19.5% | 29.2% | 38.9% | 0.70 | 0.73 |
| Poland | 38,037,110 | 196,000 | 13.8% | 86% | $101,062.56 | $115,009.19 | 18.5% | 92.3% | 138.4% | 184.5% | 4.86 | 7.43 |
| Portugal | 10,740,980 | 117,963 | 34.0% | 66% | $57,384.45 | $76,895.17 | 17.8% | 89.2% | 133.8% | 178.4% | 3.21 | 5.31 |
| Slovak Republic | 5,415,963 | 32,000 | 6.6% | 93% | $63,815.36 | $68,027.17 | 7.5% | 37.5% | 56.3% | 75.1% | 3.07 | 5.77 |
| Slovenia | 2,096,086 | - | 37.8% | 62% | $52,293.02 | $72,059.79 | 0.0% | 0.0% | 0.0% | 0.0% | 2.18 | 3.27 |
| Spain | 45,943,290 | 472,000 | 19.6% | 80% | $47,870.62 | $57,253.26 | 12.0% | 59.8% | 89.7% | 119.6% | 1.59 | 3.56 |
| Sweden | 9,699,000 | 41,000 | 33.8% | 66% | $30,589.51 | $40,928.76 | 3.6% | 18.1% | 27.1% | 36.2% | 1.00 | 1.25 |
| Switzerland | 8,074,925 | 75,525 | 29.2% | 71% | $31,191.43 | $40,299.32 | 6.7% | 33.6% | 50.3% | 67.1% | 0.71 | 1.42 |
| Turkey | 76,902,870 | 434,000 | 4.9% | 95% | $70,331.40 | $73,777.64 | - | - | - | - | 5.54 | 4.63 |
| United Kingdom | 64,090,610 | 210,000 | 43.8% | 56% | $33,283.85 | $47,862.17 | 4.3% | 21.4% | 32.1% | 42.7% | 1.15 | 1.49 |
| United States | 318,892,100 | 2,575,000 | 8.9% | 91% | $64,680.00 | $70,436.52 | 5.6% | 28.2% | 42.2% | 56.3% | 1.23 | 3.33 |
| Brazil | 199,492,400 | 1,939,000 | 30.2% | 70% | $9,708.05 | $12,639.88 | - | - | - | - | 1.66 | 1.73 |
| India | 1,267,402,000 | 6,026,000 | 54.4% | 46% | $1,861.16 | $2,873.63 | - | - | - | - | - | 0.93 |
| Egypt | 83,386,739 | 5,623,000 | 0.8% | 99% | $3,116.52 | $3,141.45 | - | - | - | - | 0.21 | 0.33 |
| Mongolia | 2,881,415 | 155,000 | 0.0% | 100% | $2,603.57 | $2,603.57 | - | - | - | - | - | 0.51 |

1. Population estimates taken from OECD Historical Population Data and Projections (1950-2050) for OECD countries, India, and Brazil and from 2014 World Bank Total Population estimates for Egypt and Mongolia.

2. Based on point estimates identified by Gower et al. 2014

3. Percentage of HCV population receiving treatment